Fortress Biotech Inc (FBIO)vsMerck & Company Inc (MRK)
FBIO
Fortress Biotech Inc
$1.99
-1.00%
HEALTHCARE · Cap: $64.37M
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 98311% more annual revenue ($67.38B vs $68.47M). FBIO leads profitability with a 163.3% profit margin vs 3.6%. FBIO trades at a lower P/E of 0.7x. FBIO earns a higher WallStSmart Score of 60/100 (C).
FBIO
Buy60
out of 100
Grade: C
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+73.0%
Fair Value
$13.57
Current Price
$1.99
$11.58 discount
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 163 of every $100 in revenue as profit
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -108.7% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : FBIO
The strongest argument for FBIO centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : FBIO
The primary concerns for FBIO are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
FBIO profiles as a mature stock while MRK is a value play — different risk/reward profiles.
FBIO carries more volatility with a beta of 1.26 — expect wider price swings.
FBIO is growing revenue faster at 14.0% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
FBIO scores higher overall (60/100 vs 44/100), backed by strong 163.3% margins and 14.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortress Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?